Donor immune cells to prevent EBV infection after stem cell transplant
Part of Blood & lymphatic, Immune system & allergy, Infections clinical trials.
This trial tests whether specially trained donor immune cells can prevent a common viral infection after a stem cell transplant. It is for people at high risk of the virus, which can cause serious problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be having (or have had) a stem cell transplant from a donor
- You must have a high risk of EBV infection, such as a positive EBV test or a past EBV-related illness
- There is no age or gender limit
- You must not have severe kidney or liver disease before getting the cells
- You must not have a severe infection or be severely malnourished at the time of treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a vaccine that may help prevent diseases caused by the Epstein-Barr virus (EBV) after a stem cell transplant. It could lower the risk of infections and related complications.
This trial tests a special immune cell therapy (EBV-AST) for people who have high levels of Epstein-Barr virus (EBV) in their blood after a stem cell transplant. The goal is to see if it can safely control the virus and prevent related complications.
This trial tests whether special immune cells (called EBV-TCR-T cells) can help clear the Epstein-Barr virus in people who still have high virus levels after a stem cell transplant. It's an experimental therapy for those whose virus hasn't responded to standard care.
This trial studies whether directly infusing donor-made immune cells (virus-fighting T-cells) is safe and feasible in people who still have viral infections after a stem cell transplant. It may help your body control infections from adenovirus, CMV, or EBV when standard antiviral treatments aren’t working.
This trial tests whether giving rituximab early after a stem cell transplant can prevent a common viral infection (EBV) from becoming serious. It may help reduce complications and improve recovery.
This trial tests a new treatment using specially prepared immune cells (called T cells) that fight the Epstein-Barr virus (EBV). It is for people who have EBV-related conditions, especially after a stem cell or organ transplant, and aims to help control the disease.
Hear when a new Prevention of EBV Infection After Allogeneic Hematopoietic Stem Cell Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.